Prozac adds indications

Executive Summary

Lilly's Prozac (fluoxetine) gets additional indications July 29 for panic disorder with or without agoraphobia, and for longer-term treatment of bulimia. Prozac previously had an indication for bulimia based on 16-week data; the longer-term indication is based on 52-week patient follow-up. The company submitted the supplemental applications in anticipation of having Prozac exclusivity through June 2004, but a court decision invalidating its longest-running patent allowed generics to enter in August 2001...